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Abstract: To assess real-world outcomes of fluocinolone acetonide (FAc) implant in treating diabetic
macular edema (DME), a systematic literature review was conducted on PubMed in order to identify
publications assessing the efficacy and safety of the FAc implant in DME in daily practice. Case
reports and randomized controlled trials were excluded. Twenty-two observational real-world studies
analyzing a total of 1880 eyes were included. Mean peak visual gain was +8.7 letters (11.3 months
post-FAc injection) and was greater for lower baseline best corrected visual acuity (BCVA) and for
more recent DME. Mean central retinal thickness (CRT) decreased 34.3% from baseline. 77.0% of the
analyzed studies reported both BCVA improvement of at least five letters and a CRT decrease by
20% or more. Rescue therapy was needed more frequently when FAc was administered for chronic
DME. FAc-induced ocular hypertension was reported in 20.1% of patients but only 0.6% needed
surgery. Cataract extraction was performed in 43.2% of phakic patients. Adequate patient selection
is essential for optimal FAc response and better safety profile. Currently positioned as second- or
third-line treatment in the management algorithm, FAc implant decreases treatment burden and
provides better letter gain when administered for more recent DME.
Keywords: fluocinolone acetonide; FAc; efficacy; safety; real-world; diabetic macular edema; DME
1. Introduction
According to the International Diabetes Federation, 700 million adults are expected to
be living with diabetes by 2045 [1]. Diabetic macular edema (DME) directly impairs central
vision making diabetes the leading cause of severe visual impairment in working-age
populations of developing countries [2,3]. Although its pathogenesis is multifactorial, it
mainly results from vasogenic changes secondary to hyperglycemia and to increased levels
of vascular endothelial growth factor (VEGF-A). It results in increased retinal hypoxia
that induces a breakdown in the blood retinal barrier and an accumulation of fluid in the
macular region [3–7]. Over the last decade, anti-VEGF injections such as ranibizumab,
aflibercept, or bevacizumab targeted this growth factor and proved to be more efficient
and safer than the traditional focal/grid laser photocoagulation [3,5,8–11].
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However, studies showed that around 30% of DME patients are non-responders to
repeated intravitreal anti-VEGF injections [6,12,13]. This can be explained by the persisting
low-grade inflammatory process that was identified in the pathogenesis of DME. Corti-
costeroids provide an alternative therapeutic strategy, particularly in chronic DME and in
patients resistant to anti-VEGF treatment. Not only do they suppress the inflammatory pro-
cess by inhibiting multiple chemokines and inflammatory cytokines, but they also interfere
with other pro-inflammatory molecules such as VEGF-A, reducing vascular permeability
and suppressing angiogenesis [14–18].
Two slow release sustained delivery systems of intraocular steroids were developed.
The 0.7 mg intravitreal dexamethasone (DEX) implant (Ozurdex®, Allergan Inc., Irvine, CA,
USA) enables extended drug release over a 6-month period [16,19–21]. The 0.19 mg intrav-
itreal fluocinolone acetonide (FAc) implant (Iluvien®, Alimera Sciences Ltd., Alpharetta,
GA, USA) provides an average release rate of 0.2 µg per day for the first 3 months followed
by a maintained concentration of 0.5–1.0 ng/mL for up to 36 months [15–17,22–24].
Strict patient selection and close follow-ups used in the FAc FAME A and B random-
ized controlled trials (RCTs) make it hard to extrapolate their findings to real-life routine
practice where patients might have co-morbidities such as ocular hypertension (OHT), poor
diabetes and blood pressure conditions with increased risk of loss of follow-up. Therefore,
findings from “real-life” observational studies, even though of a lower level of evidence
compared to interventional trials, are useful to complete our understanding of patients in
routine practice. An analysis of a significant number of these real-life studies is necessary to
minimize biases such as loss of follow-up and missing data and to draw valid conclusions.
The objective of this work is therefore to combine data from available real-world
observational studies concerning the FAc implant in order to draw potential trends and
conclusions concerning its efficacy and safety in treating DME in daily practice.
2. Materials and Methods
A search of PubMed was performed in March 2020 using the keywords (“Fluocinolone
Acetonide” OR “Iluvien”) AND (“DME” OR “DMO” OR “Diabetic Macular Edema”) in
order to identify publications assessing the efficacy and safety of the FAc implant on DME
and retrieved 64 results. Only publications that were not solely evaluating the economic
impact of the implant, which were also not case report studies, RCTs or subgroup analysis
of RCTs, were selected. Of these, only articles published in English, those with a follow-up
period of more than six months and a global population of more than 10 eyes with DME
were selected. A total of 22 studies met all inclusion criteria and were included in the
final analysis. When different patient subgroups were found for any given study, results
were presented separately for each subgroup. Because of the nature of this work, no ethics
committee approval was obtained.
To report on functional and anatomical efficacy, primary analysis was performed
on the FDA-validated criteria used in the Reinforce study for corticosteroid slow release
sustained delivery systems, using the maximum functional efficacy (peak) regardless of
the population of patients followed at this endpoint [25]. For analysis purposes, best
corrected visual acuity (BCVA) was converted from logMAR to the Early Treatment Dia-
betic Retinopathy Study (ETDRS) score when necessary. Similarly, the mean maximum
improvement of central retinal thickness (CRT) was reported. Secondary analysis was
performed on subgroups according to baseline BCVA (less than 50 letters, between 50 and
60 letters and greater than 60 letters) and to DME duration (less than 2 years, between 2 and
4 years and greater than 4 years). The mean percentage of patients who needed additional
treatments during the follow-up period was also analyzed.
To report on safety, especially concerning intraocular pressure (IOP) and lens status,
the following variables and demographic characteristics were analyzed: mean percentage
of patients with OHT at inclusion; mean percentage of FAc-induced OHT as defined by
each paper’s criteria; mean percentage of patients who needed anti-glaucoma medications
and/or glaucoma surgeries; mean percentage of phakic patients at inclusion; mean percent-
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age of lens opacification and/or cataract surgery; and rate of endophthalmitis following
the intravitreal injection.
3. Results
This section may be divided by subheadings. It should provide a concise and precise
description of the experimental results, their interpretation as well as the experimental
conclusions that can be drawn.
3.1. Study Population
All 22 observational real-world studies retained used FAc implants as second- or
third-line treatment for DME, after anti-VEGF injections and/or steroid treatment (DEX
implants and/or triamcinolone injections). A total of 1880 eyes from 1675 DME patients
were included in the final analysis (Table 1).
3.1.1. Efficacy
Visual Acuity
Studies that evaluated the functional efficacy of the FAc implant (n = 22 studies) had a
mean follow-up of 20.0 months (range: 8.5–36.0 months, median: 18.0 months) [15,26–45].
Mean baseline BCVA was 50.8 letters (range: 45.7–71.0 letters, median: 51.6 letters) and
improved to a maximum of 59.5 letters (range: 49.0–74.8 letters, median: 57.2 letters)
after FAc implant injection. All except four studies reported a BCVA improvement of
five letters or more after FAc implant injection (Figure 1). The mean peak visual gain of
+8.7 letters (range: 0.4–18.8 letters, median +8.0 letters) was observed at 11.3 months (range:
3.0–36.0 months, median: 9.0 months) (Figure 2).
Subgroup analysis of the peak BCVA gain according to the baseline BCVA and DME
duration is summarized in Table 2a. Greater BCVA gain was observed for lower base-
line BCVA (+11.0 letters for a baseline BCVA <50 letters and +7.0 letters for a baseline
BCVA <60 letters) and for more recent DME (+8.7 letters and +9.4 letters for a DME duration
between 0 and 2 years and between 2 and 4 years respectively, and +5.1 letters for a DME
duration >4 years).
Retinal Thickness
Studies that evaluated the anatomical efficacy of the FAc implant (n = 20 studies) had a
mean follow-up of 20.3 months (range: 8.5–36 months, median: 21.0 months) [26–30,32–46].
Mean baseline CRT was 516 µm (range: 328–701 µm, median: 532 µm) and decreased to
a minimum of 332 µm (range: 237–450 µm, median: 331 µm) after FAc implant injection
(Figure 3). Maximum decrease of −34.3% from baseline (range: −10.7–−55.8%, median:
−36.2%) was observed at 16.6 months (range: 4.0–36.0, median: 12.0 months). A subgroup
analysis of the peak CRT decrease according to baseline CRT is summarized in Table 2b.
Greater percentage of CRT decrease was observed for thicker baseline CRT (−44%) in
comparison with thinner baseline CRT (−18%).
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10 12 NA †††† 44.5 55.0 10.5 55.5 11.0 645.3 287.4 −55.5 287.4 −55.5 40.0 NA NA NA NA NA NA NA NA NA
Massin et al. 2016
(prior laser + avegf ‡‡‡‡) Prosp ***** 10 12 3.6 44.8 45.7 0.9 52.6 7.8 701.0 450.0 −35.8 450.0 −35.8 0.0 20.0 20.0 0.0 50.0 NA 20.0 NA 30.0 NA
Massin et al. 2016
(prior laser) Prosp 7 12 7.6 47.7 53.3 5.6 53.3 5.6 573.0 274.0 −52.2 274.0 −52.2 0.0 14.3 14.3 0.0 0.0 NA NA NA 14.3 NA
Alfaqawi et al. 2017
(all) Obs-retro 28 12 6.0 47.0 55.0 8.0 55.0 8.0 494.0 296.0 −40.1 296.0 −40.1 25.0 11.0 11.0 0.0 0.0 0.0 0.0 1.0 7.0 11.0
El Ghrably et al. 2017
(all) Obs-cons 57 14 2.6 52.7 57.8 5.1 58.3 5.6 452.0 326.0 −27.9 326.0 −27.9 NA NA 12.3 0.0 22.8 NA NA 0.0 NA NA
MEDISOFT study. 2017
(all) Obs-retro 345 14 NA 51.9 57.2 5.3 57.2 5.3 451.2 355.5 −21.2 355.5 −21.2 14.2 15.4 13.9 0.3 10.4 NA NA NA 35.7
.
NA
Meireles et al. 2017
(vitrectomized) Obs-retro 26 8.5 3.7 43.1 54.8 11.7 54.8 11.7 542.0 308.4 −43.1 308.4 −43.1 NA NA 30.8 0.0 4.0 NA NA NA 11.5 NA
Pessoa et al. 2017
(vitrectomized) Obs-retro 24 24 2.5 40.5 57.4 16.9 57.4 16.9 543.9 326.3 −40.0 326.3 −40.0 37.5 4.2 29.2 0.0 4.2 NA 100.0 NA 8.3 NA
Pessoa et al. 2017
(non-vitrectomized) Obs-retro 19 24 3.5 42.1 50.3 8.2 50.3 8.2 523.6 368.0 −29.7 368.0 −29.7 31.6 10.5 52.6 0.0 36.8 NA 42.8 NA 26.3 NA
RESPOND study. 2017
(all) Prosp 12 12 3.4 48.8 52.5 3.7 55.6 6.8 650.5 357.7 −45.0 357.7 −45.0 NA 16.7 NA 0.0 33.0 NA 25.0 NA NA NA
ICE-UK study. 2018
(all) Obs-retro 233 12 2.7 53.0 55.0 2.0 58.0 5.0 NA NA NA NA NA 19.0 25.0 15.0 0.8 11.0 NA 73.1 NA 30.0 NA
IRISS study. 2018
(all) Obs-retro 593 24 4.5 51.9 54.8 2.9 55.6 3.7 NA NA NA NA NA NA 19.1 23.3 0.8 16.4 NA NA NA 31.0 12.0
La Mantia et al. 2018
(vitrectomized) Obs-retro 7 12 NA 37.0 51.0 14.0 49.0 12.0 459.0 399.0 −13.1 399.0 −13.1 83.3 NA 0.0 NA 0.0 0.0 0.0 NA NA NA














































































































































































































































La Mantia et al. 2018
(non vitrectomized) Obs-retro 16 12 NA 51.5 59.5 8.0 63.0 11.5 416.0 344.0 −17.3 343.0 −17.5 6.3 NA 18.8 NA 0.0 0.0 0.0 NA NA NA
Rubiano et al. 2018
(all) Obs-retro 29 36 2.6 43.5 54.5 11.0 54.5 11.0 451.0 314.0 −30.4 314.0 −30.4 6.9 6.9 6.9 0.0 3.0 NA NA NA NA 12.0
USER study. 2018
(all) Obs-retro 160 24 NA NA NA NA NA NA 370.4 276.6 −25.3 276.6 −25.3 NA 35.0 24.4 1.3 22.5 NA NA NA 37.0 14.3
Coelho et al. 2019
(vitrectomized) Obs-retro 8 24 3.9 31.5 49.5 18.0 50.3 18.8 594.8 337.8 −43.2 337.8 −43.2 51.7 12.5 62.5 0.0 6.9 NA NA NA 25.0 15.0
Coney et al. 2019
(all) Obs-retro 40 12 5.3 66.2 67.7 1.5 69.3 3.1 430.9 336.5 −21.9 336.5 −21.9 NA 17.5 12.5 0.0 22.5 0.0 0.0 NA 40.0 NA
McCluskey et al. 2019
(all) Obs-retro 18 18 2.3 50.7 56.8 6.1 56.8 6.1 444.0 359.0 −19.1 359.0 −19.1 27.8 16.7 27.8 0.0 16.7 NA NA NA 44.4 NA
Vaz-Perreira et al. 2019
(all) Obs-retro 44 24 3.3 41.9 50.2 8.3 55.0 13.1 542.8 421.4 −22.4 372.0 −31.5 18.2 25.0 25.0 2.3 31.8 NA 42.9 NA NA NA
Young et al. 2019
(all) Obs-retro 21 36 2.7 53.4 62.7 9.3 66.5 13.1 410.3 252.5 −38.5 237.5 −42.1 33.0 19.0 38.1 4.7 4.8 NA NA NA 23.8 NA
* Number; † Diabetic macular edema; ‡ Baseline; ** Visual acuity; †† Central retinal thickness; ‡‡ Ocular hypertension; ††† Treatment; ‡‡‡ Observational; **** Retrospective; †††† Not
available; ‡‡‡‡ Anti-vascular endothelial growth factor; ***** Prospective.
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Figure 1. Summary of real-world studies evaluating the functional efficacy of the fluocinolone acetonide implant in the 
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Figure 1. Summary of real-world studies evaluating the functional efficacy of the fluocinolone acetonide implant in the
treatment of diabetic macular edema. (a) peak visual acuity; (b) peak visual acuity gain. Mean follow-up was 20.0 months
(n = 22 studies).
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Figure 3. Peak central retinal thickness as a fu ction of baseline ce tr l retinal thickness in real-world
studies evaluating the efficacy of the fluocinolone acetonide implant for diabetic macular edema.
Mean follow-up was 20.3 months (n = 20 studies).
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Table 2. Peak visual acuity after fluocinolone acetonide implant segmented by baseline visual acuity and duration of
diabetic macular edema (a) and peak central retinal thickness after fluocinolone acetonide implant segmented by baseline















<50 letters 14 18.6 3.9 43.7 54.7 11.0
50–60 letters 10 22.4 2.4 54.2 61.4 7.7
>60 letters 5 19.2 2.7 63.4 70.4 7.0
DME duration (years)
≤2 years 7 24.0 2.0 59.6 68.3 8.7
2–4 years 14 20.9 3.1 47.1 56.4 9.4















<400 µm 2 18.0 2.9 349 285 18
400–600 µm 20 22.0 3.3 505 328 34
>600 µm 5 14.0 2.7 640 361 44
* Number; † Diabetic macular edema; ‡ Visual acuity; § Central Retinal Thickness.
Visual and Anatomical Correlation
Of the 22 studies retained, only those assessing both functional and anatomical ef-
ficacy were used for this analysis (n = 18 studies) [26–30,32–45]. Functional efficacy was
defined as a BCVA improvement of at least five letters, while anatomical efficacy as a
CRT decrease by 20% or more (Figure 4) similarly to the definitions used by the DRCR-
net study group [47,48]. Mean follow-up duration for these studies was 20.0 months
(range: 8.5–36.0 months, median: 18.0 months). An anatomical-functional correlation
was seen in 77.0% of the studies with a mean CRT decrease of −40.5% from baseline
(range: −27.9–−55.8%, median: −40.0%) and a mean BCVA gain of +10.1 letters (range:
+5.0–+18.5 letters, median: +8.2 letters).
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Additional Treatments
Almost 30.0% of patients (range: 7.0–54.2%, median: 30.9%) needed one or more
additional intravitreal DME treatment during the follow-up period. The average duration
between treatments post-FAc implant injection was 15.4 months (range: 11.0–22.7 months,
median: 13.5 months) and was inversely proportional to the DME duration (Figure 5).
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according to chronicity of diabetic macular edema at the time of injection, in real-world studies evaluating the efficacy of
the implant for diabetic macular edema (n = 6 studies).
Safety
Intraocular Pressure
Almost one out of four injected patients (Mean 25.8%) had OHT at inclusion (range:
0.0–83.3%, median 22.2%). A total of 20.1% of patients (range: 6.9–47.4%, median: 17.5%)
had a FAc-induced OHT during the follow-up period. IOP-lowering medication was
needed in 23.4% (range: 0.0–62.5%, median: 23.8%) and only 0.6% of patients needed
IOP-lowering surgery (range: 0.0–4.7%, median: 0.0%).
Cataract
Concerning steroids-induced cataracts, 18.8% of patients included were phakic (range:
0.0–54.2%, median: 16.4%) at baseline. Of those, lens opacification was observed in 31.47%
of cases (range: 0.0–100.0%, median: 21.3%) and 43.2% (range: 0.0–100.0%, median: 33.9%)
needed cataract surgery. The mean time between FAc implant injection and cataract surgery
was 8.1 months (range: 5.25–13.4 months, median: 6.8 months) [34,39,42,44].
Endophthalmitis
Infectious complications were not described in all studies. Only one patient with
poorly controlled diabetes developed an endophthalmitis post injection and was well
managed with antibiotic treatment [26].
4. Discussion
Anti-VEGF and DEX implants are both approved as first line treatments for center-
involving DME but require regular repeated injections to maintain sufficient concentrations
in the posterior segment of the eye [49]. The FAc implant demonstrated anatomical and
functional efficacy in DME patients for up to 3 years of follow-up and is now indicated as
second- or third-line treatment in the management algorithm [23]. The rationale for using
corticosteroids in the treatment of DME is on the one hand its powerful anti-inflammatory
and anti-edematous effects. Corticosteroids suppress the inflammatory process of DME
by inhibiting prostaglandins, proinflammatory and angiogenetic mediators such as IL-6,
IL-8, MCP-1, ICAM-1, TNF-α and VEGF-A in both in vitro and in vivo settings. They also
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change the local ratio of laminin isoforms in the endothelial basal membrane, improving
the blood retinal barrier and limiting permeability and leakage by strengthening capillaries
tight junctions. They finally inhibit the inflammatory processes caused by activated Müller
glial cells that may become apoptotic with disease progression and alter the homeostasis
of the retina [50–53]. On the other hand, anti-VEGF demonstrated poor results in real-life
studies with a mean number of six letters gain due to a reduced number of injections; the
discordance between RCTs and real-life outcomes, a major issue with anti-VEGF treatments,
being mainly due to poor compliance with the tight schedule of monitoring and injections
that is mandatory to achieve best outcomes [13].
Because of the high lipophilic nature of FAc compared to dexamethasone, adequate
penetration and accumulation in the retina is possible after continuous low doses re-
lease [19,54]. This allows for fewer injections needed, less injection-related complications
and a reduction of treatment frequency by up to 87% [43,46]. Considering that 42% of a
European sample of 131 retinal patients would prefer having fewer injections for the same
results, one can see FAc implants as a way to decrease treatment burden and improve
patient’s quality of life [55]. However, our work shows that intravitreal FAc injection is
also effective in improving BCVA and reducing CRT, highlighting its particular interest in
“real-world” DME patients.
In fact, all analyzed studies reported an improvement of the BCVA with a gain that
ranged from +0.4 letters to +18.8 letters at peak efficacy. The mean peak gain of +8.7 letters
observed in the “real-world” setting is higher than the +5.3 letters gain reported by Cam-
pochiaro et al. in their pivotal FAME study, despite similar baseline visual acuity [23]. This
discrepancy can be explained by the strict and specific inclusion criteria of therapeutic trials
that do not necessarily represent all patients of routine practice, and by the possibility to
reinject more often and as needed in real-world conditions. Furthermore, this peak visual
acuity gain is similar to the one reported for DEX implants (+9.6 letters) and twice as high
as the one with anti-VEGF (+4.7 letters) [13]. FAc implants are used as second- or third-line
treatment in the management algorithm and are therefore injected for relatively “chronic”
DME. Our results show that not only do they decrease treatment burden, but they also
allow for visual improvement similar to first- or -second-line treatments used earlier in the
course of the disease.
In our review, the gain was greater for lower baseline BCVA, but also for more
recent DME. Indeed, FAc implant injections for DME older than four years were still
successful with a +5.1 letters gain, but results were less impressive than for more recent
DME. Recurrent DME causes architectural changes in the retina with ganglion cell-inner
plexiform layer thinning, glial proliferation, and photoreceptor damage at the level of the
fovea that are correlated with poor visual recuperation despite a favorable anatomical
response [56–60]. A more recent study also showed ganglion cell layer and retinal nerve
fiber layer thinning in eyes of diabetic patients with faster retinal neurodegeneration once
diabetic retinopathy (DR) develops [61].
On an anatomical level, FAc implant led to a 34.7% decrease of CRT. These results
were concordant with Campochiaro et al. who reported a 37.9% decrease from baseline [23].
In their study, Schechet et al. reported a significant decrease of mean CRT and less CRT
amplitude fluctuation after FAc over a mean follow-up period of 399 days [43]. FAc implant
provides long-term stabilization of CRT for up to 3 years, which could theoretically limit
the structural damages at the level of the fovea and allow for better visual recovery.
To our knowledge, this is the first review that demonstrates a potential functional and
anatomical response correlation of FAc implant despite its positioning in the management
algorithm of DME. This correlation was present for almost three quarters of the included
studies (77.8%) with both a BCVA gain of ≥5 letters and a CRT decrease of ≥20%. In other
terms, 8 out of 10 eyes with chronic or refractory DME had a favorable anatomical and
functional response to FAc. Overall, better functional response was observed in studies
with worse baseline BCVA. Due to the architectural damage in the retina described above,
patients with a longer DME duration (more than 5 years) had anatomical improvement but
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did not gain much visual acuity. Patients with higher baseline BCVA had fewer letters gain
but still achieved similar peak results. These “real-world” results were also described by
Eaton et al. in their USER study, they reported improvement of BCVA for patients with
the poorest VA at the time of FAc implant administration and stabilization of BCVA for
patients with better baseline VA [46].
Intravitreal additional treatments after FAc injection were needed for almost a third
of the patients. Eaton et al. demonstrated that FAc implant injection led to a significant
decrease of treatment frequency (from 2.9 months to 14.3 months post-FAc implant injection)
and consequently to less treatment burden [46]. Furthermore, our review showed that FAc
yielded better visual improvement and was sufficient as a monotherapy for a longer period
of time when administered for more recent DME. Therefore, it would be reasonable to
switch to FAc injections earlier in the treatment regimen when DME is shorter in duration
in order to delay the need for rescue therapy.
OHT is a major safety concern of steroids intravitreal injections. DEX sustained slow
release systems should be avoided in patients with advanced or uncontrolled glaucoma
or under at least dual therapy [49]. Studies have shown that patients with prior steroid
treatment who did not developed drug-induced OHT are at low risk of developing it
following the FAc implant [32,46]. Despite this high positive predictability, the latter is
contraindicated in glaucomatous patients. Interestingly though, almost one out of four
“real-world” patients (25.8%) receiving the implant had an elevated IOP >21 mmHg at
baseline, which was an exclusion criterion in the pivotal FAME study. It highlights even
more the importance of observational studies in mirroring real-life routine practice. Only
20.1% of DME patients experienced FAc-induced OHT and 23.4% needed IOP-lowering
drugs. Despite having patients with higher baseline IOP, our review shows a safer pressure
profile when compared to Campochiaro et al.’s pivotal study. This is particularly obvious
in the percentage of patients who needed IOP-lowering surgeries (0.6% in our review
versus 4.8% in FAME) [23]. Therefore, in addition to maintaining a systematic quarterly
follow-up for IOP monitoring, careful patient selection based on prior steroid-induced
OHT seems essential. Otherwise, assessment by optical coherence tomography of retinal
nerve fiber layer thickness could be of interest to evaluate early glaucomatous alteration.
Depending on local guidelines this evaluation should be done for each follow-up visit in
case of IOP increase.
Cataract extraction was needed in 43.2% of phakic patients, which is much lower than
the rate reported in the FAME study (80.0%). In their retrospective chart review, Rehak
et al. highlighted the impact of cataract progression on BCVA with restoration of vision
to levels significantly higher than pre-FAc administration after phacoemulsification [40].
Pseudophakic patients, on the other hand, presented long-term stable visual and anatomical
improvement. These findings are also consistent with the FAME study that reported a
drop in BCVA at 9–18 months due to lens opacification, followed by an improvement after
cataract surgery between 18 and 24 months [23].
Lastly, concerning infectious complications and the FAc implant safety profile, only one
case of endophthalmitis has been reported, which did not allow for any statistical analysis.
Our review has several limitations. “Real-world” observational studies are important
in completing pivotal studies by including real-life patients, but their statistical analysis can
be biased by missing data and patient’s loss of follow-up. Furthermore, studies included
were heterogenous with different primary endpoints (anatomical, functional or both).
Some pieces of information were missing and could not be assessed for all studies such
as duration of DME or time before initiation of additional treatment. Moreover, DME is
known to be affected by hypertension, hyperlipidemia, and renal function but real-world
studies only inconsistently report these data. We could also have reported the evolution of
the macular volume on SD-OCT, more precise than retinal thickness. It has already been
shown a correlation between FAc injection and the decrease of this parameter; however,
too few studies have analyzed this parameter [35,41,44]. Another limitation is the relatively
small sample of eyes included in some studies which limits the generalizability of the
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results. Nevertheless, many of these biases were compensated by the fact that we analyzed
a significant number of studies gathering almost 2000 eyes.
5. Conclusions
In conclusion, the real-life outcomes of FAc injections are comparable if not superior
to those of interventional trials. Currently positioned as second- or third-line treatment
in the management algorithm of DME, FAc implants decrease the treatment burden and
still allow for functional and anatomical improvement in such chronic patients, with even
better results for DME of shorter duration. Finally, the safety profile seems better than
initially thought in RCTs which could be reassuring for physicians.
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